NGeneBio 80% Rights Offering First Price Fixed at 1,074 KRW, Proceeds Slashed to 76.8 Billion KRW: Severe Dilution and Elevated Delisting Risk
NGeneBio finalized the first offering price at 1,074 KRW for its rights offering of 7.15 million shares representing 80% of outstanding shares, reducing the total proceeds from 224 billion KRW to approximately 7.68 billion KRW a 66% decrease.
The new shares are not subject to lock-up and carry a 25% discount, raising the risk of immediate selling pressure and further stock price declines. The largest shareholder stake will drop from 21.95% to 17.08% and could fall to 12.75% if convertible bonds are exercised.
As of Q1 2026 the company had accumulated losses of 75.8 billion KRW a debt ratio of 224% and a current ratio of 48%. Even after the capital increase an additional loss of 10.7 billion KRW could trigger a designated management issue. If the stock price falls below 1,244 KRW after trading resumes delisting risk becomes acute.
[AI Summary]With the final offering price set NGeneBio has drastically reduced its capital raising plan limiting funds to debt repayment and short-term working capital. Despite massive dilution the balance sheet improvement is marginal and the risk of delisting has intensified. Investors must consider the high probability of further price declines and governance instability.
KOSDAQ Filing Information
[Confirmation of Issuance Terms] Securities Registration Statement (Equity Securities)